We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,202.60
Bid: 1,202.40
Ask: 1,202.80
Change: -13.40 (-1.10%)
Spread: 0.40 (0.03%)
Open: 1,202.20
High: 1,236.80
Low: 1,201.20
Yest. Close: 1,216.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 1-GSK in $350 mln deal to develop cancer drugs with UK biotech firm

(Adds confirmation from Adaptimmune) June 2 (Reuters) - GlaxoSmithKline Plc has agreed a deal worth more than $350 million with British biotech company Adaptimmune to develop cancer drugs based on novel cell-based therapies. Adaptimmune said on Monday it would collaborate with GSK on

2 Jun 14 08:57

UK MORNING BRIEFING: Shares Open Higher On Positive Chinese Data

LONDON (Alliance News) - UK shares have opened slightly higher Monday on a good manufacturing PMI reading from China at the weekend and ahead of Thursday's European Central Bank meeting.<br /><br />Goldman Sachs likes the shares of UK estate agents, raising <strong>Countrywide</strong> to Buy

2 Jun 14 07:26

PRESS: Glaxo Strikes USD350 Million Oncology Deal - FT

LONDON (Alliance News) - GlaxoSmithKline PLC has completed a deal to develop new cancer drugs with a UK biotech company, which could be worth over USD350 million, the Financial Times reports Monday, quoting Adaptimmune Ltd Chief Executive James Noble. Glaxo is expected to announce a deal on

2 Jun 14 05:53

GSK in $350 mln deal to develop cancer drugs with UK biotech firm -FT

June 2 (Reuters) - GlaxoSmithKline Plc has agreed a deal worth more than $350 million with UK biotech company Adaptimmune to develop cancer drugs, the Financial Times reported on Monday. London-based GSK, which sold its cancer drugs business to Swiss drugmaker Novartis in April, is expected

1 Jun 14 23:49

Sunday share tips: Glaxo, Genel, Treatt

Buy shares of Genel Energy, Danny Fortson urged in the Sunday Times's Inside the City column. The oil explorer sold a tanker of crude from Kurdistan last month for the market rate of more than $100 a barrel. Previous sales have been below the Brent crude price because of lack of infrastructure and p

1 Jun 14 11:30

UK MIDDAY BRIEFING: Fenner Slumps On Profit Warning

LONDON (Alliance News) - Polymer products manufacturer <strong>Fenner</strong> saw its shares plummet Friday, after it issued a profit warning that it blamed on a further deterioration in trading in the US and the loss of a profitable contract in Australia.<br /><br />It is the biggest faller

30 May 14 11:46

London midday: Miners pull UK markets lower, but Smith & Nephew rises

- Mining stocks lower on iron ore, China concerns - Fenner issues profit warning - M&A continues to boost Smith & Nephew techMARK 2,820.23 +0.39% FTSE 100 6,860.62 -0.16% FTSE 250 16,039.31 +0.53% Weakness in the mining sector dragged the UK stock market from a two-week high on Friday, despite M&A

30 May 14 11:34

RPT-Fitch Affirms & Withdraws 8 Non-Financial Corporate Issuers' Short-Term Ratings

(Repeat for additional subscribers) May 30 (Reuters) - (The following statement was released by the rating agency) Fitch Ratings has affirmed and simultaneously withdrawn the Short-term Issuer Default Ratings of AstraZeneca PLC (F1+), Compass Group PLC (F2), GlaxoSmithkline PLC /Gla

30 May 14 10:49

TOP NEWS: UK Consumer Confidence Hits Nine-Year High

LONDON (Alliance News) - The following is a summary of top news stories Friday.<br />----------<br /><strong>COMPANIES</strong><br />----------<br />Polymer products manufacturer <strong>Fenner</strong> PLC said underlying pretax profit for the year will be 10% to 15% below the prevailing mark

30 May 14 10:28

London pre-open: Flat start ahead of consumer confidence, German retail data

A flat start is expected for London-listed stocks this morning ahead of today's UK consumer confidence report and German retail data. City sources predict the FTSE 100 will open almost unchanged from yesterday's close of 6,871.29. According to forecasts, the GfK's consumer sentiment index is exp

30 May 14 07:28

UK MORNING BRIEFING: Fenner Drops 15% On Profit Warning

LONDON (Alliance News) - UK shares have opened flat Friday, with European markets on hold ahead of a key European Central Bank meeting next week.<br /><br />FTSE 250 polymer products maker <strong>Fenner</strong> PLC said underlying pretax profit for the year to August 31 could fall by 10% to

30 May 14 07:26

GlaxoSmithKline gauges buyer interest for mature drug portfolio

GlaxoSmithKline (GSK) is rumoured to have approached a number of private equity firms to gauge the interest for a range of its older drugs as it attempts to refresh its portfolio. According to various reports, the pharmaceutical group has contacted companies including Advent International, Blacksto

30 May 14 06:44

PRESS: Glaxo Puts Some Of Older Drugs On Block - FT

LONDON (Alliance News) - GlaxoSmithKline PLC has invited private equity firms to bid for some of its older drugs in the latest step by Chief Executive Andrew Witty to reshape the UK?s biggest drugmaker, the Financial Times reports Friday, citing people familiar with the situation. Private e

30 May 14 05:48

UPDATE 3-GSK invites private equity to bid for older drugs -sources

* GSK weighing disposal of established drugs in Western markets * Part of wider reshaping of British drugmaker's business * Other pharma firms also reviewing mature drug portfolios * GSK said to be in "no rush" to divest older non-core assets (Adds detail on profitability, par

29 May 14 18:57

UPDATE 2-GSK invites private equity to bid for older drugs -sources

* GSK weighing disposal of established drugs in Western markets * Part of wider reshaping of British drugmaker's business * Other pharma firms also reviewing mature drug portfolios * GSK said to be in "no rush" to divest older non-core assets (Adds more detail on valuation, ba

29 May 14 16:44

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.